Rasagiline
Identifieur interne : 001435 ( Main/Exploration ); précédent : 001434; suivant : 001436Rasagiline
Auteurs : Anthony Schapira [Royaume-Uni] ; Guy Bate [Royaume-Uni] ; Peter KirkpatrickSource :
- Nature Reviews Drug Discovery [ 1474-1776 ] ; 2005-08.
Abstract
Rasagiline (Azilect; Lundbeck/Teva Pharmaceutical Industries) was given marketing approval by the EMEA for the treatment of Parkinson's disease in February 2005. It is the first in a new generation of selective monoamine oxidase inhibitors, and acts to alleviate the dopaminergic deficit characteristic of the disease.
Url:
DOI: 10.1038/nrd1803
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rasagiline</title><author><name sortKey="Schapira, Anthony" sort="Schapira, Anthony" uniqKey="Schapira A" first="Anthony" last="Schapira">Anthony Schapira</name></author><author><name sortKey="Bate, Guy" sort="Bate, Guy" uniqKey="Bate G" first="Guy" last="Bate">Guy Bate</name></author><author><name sortKey="Kirkpatrick, Peter" sort="Kirkpatrick, Peter" uniqKey="Kirkpatrick P" first="Peter" last="Kirkpatrick">Peter Kirkpatrick</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C53EDBB7F673A33C12D33AC9B93DBB5D5F1B2FF3</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1038/nrd1803</idno><idno type="url">https://api.istex.fr/document/C53EDBB7F673A33C12D33AC9B93DBB5D5F1B2FF3/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001050</idno><idno type="wicri:Area/Main/Curation">000E60</idno><idno type="wicri:Area/Main/Exploration">001435</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Rasagiline</title><author><name sortKey="Schapira, Anthony" sort="Schapira, Anthony" uniqKey="Schapira A" first="Anthony" last="Schapira">Anthony Schapira</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical Neurosciences, Royal Free and University College Medical School, London, NW3 2PF</wicri:regionArea><wicri:noRegion>NW3 2PF</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Royaume-Uni</country></affiliation></author><author><name sortKey="Bate, Guy" sort="Bate, Guy" uniqKey="Bate G" first="Guy" last="Bate">Guy Bate</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>IMS Health, 7 Harewood Avenue, London, NW1 6JB</wicri:regionArea><wicri:noRegion>NW1 6JB</wicri:noRegion></affiliation><affiliation><wicri:noCountry code="no comma">E-mail: gbate@uk.imshealth.com</wicri:noCountry></affiliation></author><author><name sortKey="Kirkpatrick, Peter" sort="Kirkpatrick, Peter" uniqKey="Kirkpatrick P" first="Peter" last="Kirkpatrick">Peter Kirkpatrick</name><affiliation><wicri:noCountry code="syntax">???</wicri:noCountry></affiliation><affiliation><wicri:noCountry code="no comma">E-mail: p.kirkpatrick@nature.com</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j">Nature Reviews Drug Discovery</title><idno type="ISSN">1474-1776</idno><idno type="eISSN">1474-1784</idno><imprint><publisher>Nature Publishing Group</publisher><date type="published" when="2005-08">2005-08</date><biblScope unit="volume">4</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="625">625</biblScope><biblScope unit="page" to="626">626</biblScope></imprint><idno type="ISSN">1474-1776</idno></series><idno type="istex">C53EDBB7F673A33C12D33AC9B93DBB5D5F1B2FF3</idno><idno type="DOI">10.1038/nrd1803</idno><idno type="ArticleID">nrd1803</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1474-1776</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="eng">Rasagiline (Azilect; Lundbeck/Teva Pharmaceutical Industries) was given marketing approval by the EMEA for the treatment of Parkinson's disease in February 2005. It is the first in a new generation of selective monoamine oxidase inhibitors, and acts to alleviate the dopaminergic deficit characteristic of the disease.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country></list><tree><noCountry><name sortKey="Kirkpatrick, Peter" sort="Kirkpatrick, Peter" uniqKey="Kirkpatrick P" first="Peter" last="Kirkpatrick">Peter Kirkpatrick</name></noCountry><country name="Royaume-Uni"><noRegion><name sortKey="Schapira, Anthony" sort="Schapira, Anthony" uniqKey="Schapira A" first="Anthony" last="Schapira">Anthony Schapira</name></noRegion><name sortKey="Bate, Guy" sort="Bate, Guy" uniqKey="Bate G" first="Guy" last="Bate">Guy Bate</name><name sortKey="Schapira, Anthony" sort="Schapira, Anthony" uniqKey="Schapira A" first="Anthony" last="Schapira">Anthony Schapira</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001435 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001435 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:C53EDBB7F673A33C12D33AC9B93DBB5D5F1B2FF3
|texte= Rasagiline
}}
| This area was generated with Dilib version V0.6.23. |  |